Toll-Like Receptor Expression in the Blood and Brain of Patients and a Mouse Model of Parkinson's Disease
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Accumulating evidence supports a role for the immune system in the pathogenesis of Parkinson's disease. Importantly, recent preclinical studies are now suggesting a specific contribution of inflammation to the α-synuclein-induced pathology seen in this condition. METHODS: We used flow cytometry and western blots to detect toll-like receptor 2 and 4 expression in blood and brain samples of Parkinson's disease patients and mice overexpressing human α-synuclein. To further assess the effects of α-synuclein overexpression on the innate immune system, we performed a longitudinal study using Thy1.2-α-synuclein mice that expressed a bicistronic DNA construct (reporter genes luciferase and green fluorescent protein) under the transcriptional control of the murine toll-like receptor 2 promoter. RESULTS: Here, we report increases in toll-like receptors 2 and 4 expression in circulating monocytes and of toll-like receptor 4 in B cells and in the caudate/putamen of Parkinson's disease patients. Monthly bioluminescence imaging of Thy1.2-α-synuclein mice showed increasing toll-like receptor 2 expression from 10 months of age, although no change in toll-like receptor 2 and 4 expression was observed in the blood and brain of these mice at 12 months of age. Dexamethasone treatment starting at 5 months of age for 1 month significantly decreased the microglial response in the brain of these mice and promoted functional recovery as observed using a wheel-running activity test. CONCLUSION: Our results show that toll-like receptors 2 and 4 are modulated in the blood and brain of Parkinson's disease patients and that overexpression of α-synuclein leads to a progressive microglial response, the inhibition of which has a beneficial impact on some motor phenotypes of an animal model of α-synucleinopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2. Toll-like receptor (TLR)2 and TLR4 expression in the brain of Parkinson’s disease (PD) patients. (A-B) Western blot quantification of TLR2, TLR4, and molecules involved in their downstream pathways (myeloid differentiation primary response gene (88) [MyD88], TIR-less splice variant of TIR-domain-containing adapter-inducing interferon-β [TRIS], nuclear factor κB [NF-κB]in the striatum of PD patients (n=7) compared to age- and gender-matched controls (CTL or C) (n=6). Data are expressed as a ratio over β-actin. All data are expressed as group means±SEM. Statistical analyses were performed using an unpaired Student’s t test with a Welch correction in case of unequal variance. *P<.05; **P<.01.](https://figures.cochat.ai/paper-figures/4699b87a783b4139b5544152384eeb27/toll-like-receptor-expression-in-the-blood-and-brain-of-patients-and-a-mouse-figure-2.jpg)
![Figure 3. Toll-like receptor (TLR)2 and TLR4 expression in the brain of Thy1.2-α-synuclein (αSyn)× TLR2-GFP-fluc mice. Schematic diagram of the Thy1.2-αSyn (Rockenstein et al., 2002) and TLR2-GFP-fluc (Lalancette-Hebert et al., 2009) constructs that were used to generate the Thy1.2-αSyn×TLR2-GFP-fluc mice. (B) Immunofluorescent staining of human αSyn (hαSyn) showing none in a littermate nontransgenic for the hαSyn gene and strong expression in the transgenic mouse. Treatment with Proteinase K confirms the presence of αSyn in the substantia nigra of Thy1.2-αSyn×TLR2-GFP-fluc mice. (C) Western blot quantification of TLR2, TLR4, and molecules involved in their pathways (myeloid differentiation primary response gene (88) [MyD88], TIR-less splice variant of TIR-domain-containing adapter-inducing interferon-β [TRIS], Nuclear factor κB [NF-κB]-p65), as well as hαSyn and total αSyn, in the striatum of Thy1.2-αSyn×TLR2-GFP-fluc mice (n=9) compared to wild type×TLR2-GFP-fluc littermates (n=9) at 12 months of age. Western blot data are expressed as a ratio over β-actin. All data are expressed as group means±SEM. Statistical analyses were performed using an unpaired Student’s t test with a Welch correction in case of unequal variance. hαSyn-/-, TLR2-GFP-fluc mice; hαSyn-/-, Thy1.2-αSyn×TLR2-GFP-fluc mice; SNCA, synuclein, Alpha (Non A4 Component Of Amyloid Precursor); TRIS, TIR-less splice variant of TIR-domain-containing adapter-inducing interferon-β (TRIF). Scale bar=100 µm, inset=25 µm, lower row=50 µm.](https://figures.cochat.ai/paper-figures/ab7ba182cb3d400492a3d1aa5bb1d6ba/toll-like-receptor-expression-in-the-blood-and-brain-of-patients-and-a-mouse-figure-3.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased gut permeability with intestine α-synuclein accumulation, elevated blood and brain levels of TLR2 and TLR4, and reduced blood levels of the LPS-binding protein have been detected in subjects with”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [412]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“It has been suggested that TLR2 expression is upregulated in PD postmortem human brains.291,292”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [291]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378 · cited 1×
“All patients had been diagnosed according to the diagnostic criteria of the UK PD Society Brain Bank (Hughes et al., 1992).”
MethodSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383 · cited 1×
“The involvement of αSyn to PD pathogenesis is further supported by the fact that overexpression of this protein, as a consequence of either a duplication or triplication of the gene, leads to early-onset PD (Singleton et al., 2003; Chartier-Harlin et al., 2004).”
BackgroundMcGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990 · cited 1×
“It has in fact long been recognized that PD brains are characterized by the presence of a microglial reaction (McGeer et al., 1988; McGeer and McGeer, 2004), which increases with disease duration (Croisier et al.”
BackgroundWiklund, R. A., & Rosenbaum, S. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710163371606 · Cited by 2,149
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029 · cited 1×
“The involvement of αSyn to PD pathogenesis is further supported by the fact that overexpression of this protein, as a consequence of either a duplication or triplication of the gene, leads to early-onset PD (Singleton et al., 2003; Chartier-Harlin et al., 2004).”
BackgroundLang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 1,994 · cited 2×
“In PD, there is a degeneration of the nigrostriatal dopaminergic pathway with formation of Lewy bodies, which together form the pathological hallmarks of the disease (Lang and Lozano, 1998).”
BackgroundMethodZhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265 · cited 1×
“In particular, aggregated forms of this protein secreted by neurons of the substantia nigra (SN) could do this, leading to the production of pro-inflammatory mediators and thereby exacerbating neuronal death (Zhang et al., 2005; Su et al., 2008; Theodore et al., 2008; Lee et al., 2010).”
BackgroundKim, C., Ho, D.-H., Suk, J.-E., You, S., Michael, S., Kang, J., Joong Lee, S., Masliah, E., Hwang, D., Lee, H.-J., et al. (2013) · Nature Communications · doi:10.1038/ncomms2534 · Cited by 856 · cited 3×
“It has recently been reported that oligomers of Syn, but not aggregates, can act as TLR2 ligands (Kim et al., 2013).”
BackgroundInfluentialMicroglial activation and dopamine terminal loss in early Parkinson's disease
Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., & Torizuka, T. (2005) · Annals of Neurology · doi:10.1002/ana.20338 · Cited by 843 · cited 1×
“For commercial re-use, please contact journals.permissions@oup.com Background: Accumulating evidence supports a role for the immune system in the pathogenesis of Parkinson’s disease.”
BackgroundBlum-Degena, D., Müller, T., Kuhn, W., Gerlach, M., Przuntek, H., & Riederer, P. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12192-7 · Cited by 801 · cited 1×
“, 2009), and elevated IL-1 levels have been reported in the cerebrospinal fluid of PD patients (Blum-Degen et al., 1995).”
BackgroundBlood–brain barrier dysfunction in parkinsonian midbrain in vivo
Kortekaas, R., Leenders, K. L., van Oostrom, J. C. H., Vaalburg, W., Bart, J., Willemsen, A. T. M., & Hendrikse, N. H. (2005) · Annals of Neurology · doi:10.1002/ana.20369 · Cited by 733
Recognition and Signaling by Toll-Like Receptors
West, A. P., Koblansky, A. A., & Ghosh, S. (2006) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.21.122303.115827 · Cited by 720 · cited 2×
“Upon stimulation, TLRs trigger signalling pathways that result in the activation of NF-κB, p38 mitogen-activated protein kinase, and Jun-N-terminal kinase (JNK) (Dunne and O’Neill, 2003; West et al., 2006).”
MethodDunne, A., & O'Neill, L. A. J. (2003) · Science's STKE · doi:10.1126/stke.2003.171.re3 · Cited by 711 · cited 2×
“Upon stimulation, TLRs trigger signalling pathways that result in the activation of NF-κB, p38 mitogen-activated protein kinase, and Jun-N-terminal kinase (JNK) (Dunne and O’Neill, 2003; West et al., 2006).”
MethodInflammation and neurodegeneration in Parkinson's disease
McGeer, P. L., & McGeer, E. G. (2004) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.01.005 · Cited by 625 · cited 2×
“It has in fact long been recognized that PD brains are characterized by the presence of a microglial reaction (McGeer et al., 1988; McGeer and McGeer, 2004), which increases with disease duration (Croisier et al., 2005).”
BackgroundCD14 and Toll-Like Receptors 2 and 4 Are Required for Fibrillar Aβ-Stimulated Microglial Activation
Reed-Geaghan, E. G., Savage, J. C., Hise, A. G., & Landreth, G. E. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3158-09.2009 · Cited by 591 · cited 1×
“upon Syn stimulation, as it is the case with A in AD (Reed-Geaghan et al., 2009).”
Polarization of the Effects of Autoimmune and Neurodegenerative Risk Alleles in Leukocytes
Raj, T., Rothamel, K., Mostafavi, S., Ye, C., Lee, M. N., Replogle, J. M., Feng, T., Lee, M., Asinovski, N., Frohlich, I., et al. (2014) · Science · doi:10.1126/science.1249547 · Cited by 506 · cited 1×
“A recent study has further highlighted the importance of monocytes in PD by reporting a monocyte-specific expression quantitative trait locus among PD variants (Raj et al., 2014).”
BackgroundRockenstein, E., Mallory, M., Hashimoto, M., Song, D., Shults, C. W., Lang, I., & Masliah, E. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10231 · Cited by 502
Synuclein activates microglia in a model of Parkinson's disease
Su, X., Maguire-Zeiss, K. A., Giuliano, R., Prifti, L., Venkatesh, K., & Federoff, H. J. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.006 · Cited by 474 · cited 1×
“In particular, aggregated forms of this protein secreted by neurons of the substantia nigra (SN) could do this, leading to the production of proinflammatory mediators and thereby exacerbating neuronal death (Zhang et al., 2005; Su et al., 2008; Theodore et al., 2008; Lee et al., 2010).”
BackgroundCroisier, E., Moran, L. B., Dexter, D. T., Pearce, R. K., & Graeber, M. B. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-14 · Cited by 414
Theodore, S., Cao, S., McLean, P. J., & Standaert, D. G. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31818e5e99 · Cited by 367
A Progressive Mouse Model of Parkinson’s Disease: The Thy1-aSyn (“Line 61”) Mice
Chesselet, M.-F., Richter, F., Zhu, C., Magen, I., Watson, M. B., & Subramaniam, S. R. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0104-2 · Cited by 346
Alterations of T-lymphocyte populations in Parkinson disease
Baba, Y., Kuroiwa, A., Uitti, R. J., Wszolek, Z. K., & Yamada, T. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.07.005 · Cited by 336 · cited 1×
“literature presents inconsistent results regarding changes in circulating blood cells, some populations (including CD4+, CD8+ T cells, and B cells) (Bas et al., 2001; Baba et al., 2005; Niwa et al., 2012; Stevens et al., 2012) are characterized by changes in their total number in sporadic forms of PD.”
ResultToward a Refined Definition of Monocyte Subsets
Ziegler-Heitbrock, L., & Hofer, T. P. J. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00023 · Cited by 298 · cited 2×
“Classification of blood monocytes follows a time course of activation (Ziegler-Heitbrock and Hofer, 2013) for which classical monocytes make up the vast majority of monocytes under physiological conditions, and which are associated with a resting state Intermediate monocytes exhibit a phenotype…”
BackgroundToll-Like Receptor 4 Promotes α-Synuclein Clearance and Survival of Nigral Dopaminergic Neurons
Stefanova, N., Fellner, L., Reindl, M., Masliah, E., Poewe, W., & Wenning, G. K. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.04.013 · Cited by 272
Lee, E.-J., Woo, M.-S., Moon, P.-G., Baek, M.-C., Choi, I.-Y., Kim, W.-K., Junn, E., & Kim, H.-S. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903480 · Cited by 267 · cited 1×
“In particular, aggregated forms of this protein secreted by neurons of the substantia nigra (SN) could do this, leading to the production of proinflammatory mediators and thereby exacerbating neuronal death (Zhang et al., 2005; Su et al., 2008; Theodore et al., 2008; Lee et al., 2010).”
BackgroundLymphocyte populations in Parkinson's disease and in rat models of parkinsonism
Bas, J. (2001) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(00)00422-7 · Cited by 250 · cited 3×
“literature presents inconsistent results regarding changes in circulating blood cells, some populations (including CD4+, CD8+ T cells, and B cells) (Bas et al., 2001; Baba et al., 2005; Niwa et al., 2012; Stevens et al., 2012) are characterized by changes in their total number in sporadic forms of PD.”
BackgroundResultWatson, M. B., Richter, F., Lee, S. K., Gabby, L., Wu, J., Masliah, E., Effros, R. B., & Chesselet, M.-F. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.06.025 · Cited by 241
Castaño, A., Herrera, A. J., Cano, J., & Machado, A. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00799.x · Cited by 238
Ros-Bernal, F., Hunot, S., Herrero, M. T., Parnadeau, S., Corvol, J.-C., Lu, L., Alvarez-Fischer, D., Carrillo-de Sauvage, M. A., Saurini, F., Coussieu, C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017820108 · Cited by 231
Screening of innate immune receptors in neurodegenerative diseases: A similar pattern
Letiembre, M., Liu, Y., Walter, S., Hao, W., Pfander, T., Wrede, A., Schulz-Schaeffer, W., & Fassbender, K. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.08.018 · Cited by 228 · cited 1×
“2-αSyn mice (Stefanova et al., 2007; Letiembre et al., 2009; Watson et al., 2012).”
BackgroundStefanova, N., Reindl, M., Neumann, M., Kahle, P. J., Poewe, W., & Wenning, G. K. (2007) · Movement Disorders · doi:10.1002/mds.21671 · Cited by 217 · cited 1×
“2- Syn mice (Stefanova et al., 2007; Letiembre et al., 2009; Watson et al., 2012).”
Frisancho-Kiss, S., Davis, S. E., Nyland, J. F., Frisancho, J. A., Cihakova, D., Barrett, M. A., Rose, N. R., & Fairweather, D. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.6710 · Cited by 212 · cited 1×
“For example, testosterone decreases the expression of TLR4 in monocytes (Frisancho-Kiss et al., 2007).”
BackgroundExpression and regulation of toll-like receptors in cerebral endothelial cells
Nagyőszi, P., Wilhelm, I., Farkas, A. E., Fazakas, C., Dung, N. T. K., Haskó, J., & Krizbai, I. A. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.07.002 · Cited by 201
Fernagut, P. O., Hutson, C. B., Fleming, S. M., Tetreaut, N. A., Salcedo, J., Masliah, E., & Chesselet, M. F. (2007) · Synapse · doi:10.1002/syn.20456 · Cited by 196 · cited 2×
“For example, testosterone decreases the expression of TLR4 in monocytes (Frisancho-Kiss et al., 2007).”
Modelling of Parkinson's disease in mice
Chesselet, M.-F., & Richter, F. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70227-7 · Cited by 192 · cited 2×
“2-αSyn mouse model at 6 months of age affects the striatal dopamine release, leading to high levels of extracellular dopamine and translating into changes in motor activity (Chesselet and Richter, 2011).”
BackgroundReduced T helper and B lymphocytes in Parkinson's disease
Stevens, C. H., Rowe, D., Morel-Kopp, M.-C., Orr, C., Russell, T., Ranola, M., Ward, C., & Halliday, G. M. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2012.07.015 · Cited by 189 · cited 5×
“To our knowledge, differences in B lymphocyte count between males and females has never been reported, but gender has been seen to affect the number of monocytes (Stevens et al., 2012), although published results are, again, inconsistent.”
BackgroundResultInfluentialCircadian dysfunction in a mouse model of Parkinson's disease
Kudo, T., Loh, D. H., Truong, D., Wu, Y., & Colwell, C. S. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.08.003 · Cited by 188 · cited 1×
“2-αSyn mice thus display a striking reduction in activity over a 24-hour period in free-running wheels with lower nighttime activity as early as 3-4 months of age, which seems to relate to selective deficits in the expression of circadian rhythms of locomotor activity (Kudo et al., 2011).”
BackgroundHigh dose steroid treatment in cerebral infarction.
Norris, J. W., & Hachinski, V. C. (1986) · BMJ · doi:10.1136/bmj.292.6512.21 · Cited by 163 · cited 2×
“To evaluate the contribution of the observed inflammatory response in this mouse model, we administered dexamethasone, which has long been used clinically for the treatment of neuroinflammation (Anderson and Cranford, 1979; Norris and Hachinski, 1986).”
MethodGrage‐Griebenow, E., Lorenzen, D., Fetting, R., Flad, H., & Ernst, M. (1993) · European Journal of Immunology · doi:10.1002/eji.1830231213 · Cited by 150 · cited 1×
“Classification of blood monocytes follows a time course of activation (Ziegler-Heitbrock and Hofer, 2013) for which classical monocytes make up the vast majority of monocytes under physiological conditions, and which are associated with a resting state Intermediate monocytes exhibit a phenotype between classical and p…”
BackgroundLalancette-Hébert, M., Phaneuf, D., Soucy, G., Weng, Y. C., & Kriz, J. (2009) · Brain · doi:10.1093/brain/awn345 · Cited by 136 · cited 3×
“, 2002) and TLR2-GFP-fluc (Lalancette-Hebert et al., 2009) constructs that were used to generate the Thy1.”
MethodInfluentialNiwa, F., Kuriyama, N., Nakagawa, M., & Imanishi, J. (2012) · Geriatrics & Gerontology International · doi:10.1111/j.1447-0594.2011.00740.x · Cited by 125 · cited 2×
“…presents inconsistent results regarding changes in circulating blood cells, some populations (including CD4+, CD8+ T cells, and B cells) (Bas et al., 2001; Baba et al., 2005; Niwa et al., 2012; Stevens et al., 2012) are characterized by changes in their total number in sporadic forms of PD.”
BackgroundResultGardai, S. J., Mao, W., Schüle, B., Babcock, M., Schoebel, S., Lorenzana, C., Alexander, J., Kim, S., Glick, H., Hilton, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071634 · Cited by 108
Antitumor response of CD14+/CD16+ monocyte subpopulation
Szaflarska, A., Baj‐Krzyworzeka, M., Siedlar, M., Węglarczyk, K., Ruggiero, I., Hajto, B., & Zembala, M. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2004.05.027 · Cited by 100 · cited 1×
“, 2008) and interleukin (IL)-12 (Szaflarska et al., 2004).”
Circulating interleukin-10 and interleukin-12 in Parkinson’s disease
Rentzos, M., Nikolaou, C., Andreadou, E., Paraskevas, G. P., Rombos, A., Zoga, M., Tsoutsou, A., Boufidou, F., Kapaki, E., & Vassilopoulos, D. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2008.01103.x · Cited by 99
Jagannathan, M., Hasturk, H., Liang, Y., Shin, H., Hetzel, J. T., Kantarci, A., Rubin, D., McDonnell, M. E., Van Dyke, T. E., Ganley-Leal, L. M., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901517 · Cited by 99
Disruption of the blood-brain barrier in parkinson's disease: curse or route to a cure?
Lee, H. (2014) · Frontiers in Bioscience · doi:10.2741/4206 · Cited by 96
Tremblay, C., St-Amour, I., Schneider, J., Bennett, D. A., & Calon, F. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31822c62cf · Cited by 95
Self-citationMinghetti, L., Nicolini, A., Polazzi, E., Greco, A., Perretti, M., Parente, L., & Levi, G. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702423 · Cited by 95 · cited 1×
“Dexamethasone blocks microglial activation by inhibiting major histocompatibility complex class II expression through downregulating cyclooxygenase 2 and inducible nitric oxide synthase production (Minghetti et al., 1999).”
BackgroundCharacterization of peripheral hematopoietic stem cells and monocytes in Parkinson's disease
Funk, N., Wieghofer, P., Grimm, S., Schaefer, R., Bühring, H., Gasser, T., & Biskup, S. (2013) · Movement Disorders · doi:10.1002/mds.25300 · Cited by 81 · cited 1×
“Very few studies have assessed changes in the number of monocytes, but one has described an increase, whereas the other has reported no change (Stevens et al., 2012; Funk et al., 2013).”
BackgroundBelge, G., Meyer, A., Klemke, M., Burchardt, K., Stern, C., Wosniok, W., Loeschke, S., & Bullerdiek, J. (2008) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20505 · Cited by 81
Inflammation and neurodegeneration: the story ‘retolled’
Drouin‐Ouellet, J., & Cicchetti, F. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.07.002 · Cited by 80 · cited 4×
“More targeted studies have revealed a possible role for toll-like receptors (TLRs) in the pathological processes underlying neurodegenerative disorders, including PD (Panaro et al., 2008; Ros-Bernal et al., 2011; Cote et al., 2011; Drouin-Ouellet et al., 2011; Drouin-Ouellet and Cicchetti, 2012; Kim et al., 2013) For…”
BackgroundInfluentialSelf-citationTremblay, C., Pilote, M., Phivilay, A., Emond, V., Bennett, D. A., & Calon, F. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-12411 · Cited by 78
Corticosteroids in ischemic stroke.
Anderson, D. C., & Cranford, R. E. (1979) · Stroke · doi:10.1161/01.str.10.1.68 · Cited by 63
Panaro, M. A., Lofrumento, D. D., Saponaro, C., De Nuccio, F., Cianciulli, A., Mitolo, V., & Nicolardi, G. (2008) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923970802278557 · Cited by 63 · cited 3×
“…have revealed a possible role for toll-like receptors (TLRs) in the pathological processes underlying neurodegenerative disorders, including PD (Panaro et al., 2008; Ros-Bernal et al., 2011; Cote et al., 2011; Drouin-Ouellet et al., 2011; Drouin-Ouellet and Cicchetti, 2012; Kim et al.,…”
BackgroundInfluentialβ1-integrin-dependent migration of microglia in response to neuron-released α-synuclein
Kim, C., Cho, E.-D., Kim, H.-K., You, S., Lee, H.-J., Hwang, D., & Lee, S.-J. (2014) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.6 · Cited by 60
The critical role of the MyD88-dependent pathway in non-CNS MPTP-mediated toxicity
Côté, M., Drouin‐Ouellet, J., Cicchetti, F., & Soulet, D. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.02.017 · Cited by 51 · cited 5×
“In previous work, we have explored the role of the MyD88-dependant pathways in the context of toxin-induced animal models of PD (Cote et al., 2011; Drouin-Ouellet et al., 2011; Drouin-Ouellet and Cicchetti, 2012).”
BackgroundInfluentialSelf-citationScreening of Toll-Like Receptors Expression in Multiple System Atrophy Brains
Brudek, T., Winge, K., Agander, T. K., & Pakkenberg, B. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1020-5 · Cited by 43 · cited 1×
“In fact, multiple system atrophy patients express elevated levels of TLR4 mRNA in the SN, striatum, cortex, and nucleus dentatus (Brudek et al., 2013).”
BackgroundThe role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration
Drouin-Ouellet, J., Gibrat, C., Bousquet, M., Calon, F., Kriz, J., & Cicchetti, F. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-137 · Cited by 39
Self-citationThe Antibody MY4 Recognizes CD14 on Porcine Monocytes and Macrophages
Ziegler-Heitbrock, H. W. L., APPL, B., Käfferlein, E., Löffler, T., JAHN‐HENNINGER, H., Gutensohn, W., Nores, J. E. R., McCullough, K. C., Passlick, B., Labéta, M. O., et al. (1994) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.1994.tb03497.x · Cited by 33 · cited 1×
“…conditions, and which are associated with a resting state Intermediate monocytes exhibit a phenotype between classical and proinflammatory with increased antigen presenting activity (Grage-Griebenow et al., 1993) as well as higher proangiogenic capacity (Ziegler-Heitbrock et al., 1994).”
BackgroundHan, K.-J., Yang, Y. F., Xu, L., & Shu, H. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.072231 · Cited by 33 · cited 2×
“All patients had been diagnosed according to the diagnostic criteria of the UK PD Society Brain Bank (Hughes et al., 1992).”
MethodA central role for monocytes in Toll‐like receptor‐mediated activation of the vasculature
Ward, J. R., Francis, S., Marsden, L., Suddason, T., Lord, G. M., Dower, S., Crossman, D. C., & Sabroe, I. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03071.x · Cited by 29 · cited 1×
“Of interest, IL-1 has been shown to activate monocytes via TLR4 (Ward et al., 2009), and elevated IL-1 levels have been reported in the cerebrospinal fluid of PD patients (Blum-Degen et al.”
BackgroundMyD88 deficiency results in both cognitive and motor impairments in mice
Drouin‐Ouellet, J., LeBel, M., Filali, M., & Cicchetti, F. (2012) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2012.02.007 · Cited by 25 · cited 1×
“Wheel activity system: Spontaneous running activity was evaluated during the active cycle of the mouse using activity wheels, as previously described (Drouin-Ouellet et al., 2012).”
MethodSelf-citation
Research works printed but not linked: 6
- 2013, Neurochemical research, 38, 1252, 10.1007/s11064-013-1020-5 · DOI · Paper page
- 2013, Movement disorders : official journal of the Movement Disorder Society, 28, 392, 10.1002/mds.25300 · DOI · Paper page
- 2010, Journal of Biological Chemistry, 285, 12543, 10.1074/jbc.m109.072231 · DOI
- 2009, The Journal of Immunology, 183, 7461, 10.4049/jimmunol.0901517 · DOI · Paper page
- 2014, Experimental & molecular medicine, 46, e91, 10.1038/emm.2014.6 · DOI · Paper page
- 2011, PNAS, 108, 6632, 10.1073/pnas.1017820108 · DOI · Paper page
Cited by
Role of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668
“It has been suggested that TLR2 expression is upregulated in PD postmortem human brains.(291,292) α-synuclein released from neurons can act as an endogenous DAMPs, bind to TLR2, and then be endocytosed and transported to lysosomes for degradation or spreading to adjacent cells.”
BackgroundThe Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders
Socała, K., Doboszewska, U., Szopa, A., Serefko, A., Włodarczyk, M., Zielińska, A., Poleszak, E., Fichna, J., & Wlaź, P. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105840 · Cited by 857
Dysbiosis of gut microbiota and microbial metabolites in Parkinson's disease
Sun, M.-F., & Shen, Y.-Q. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.04.004 · Cited by 445
Exploring Braak’s hypothesis of Parkinson’s disease
Rietdijk, C. D., Perez-Pardo, P., Garssen, J., van Wezel, R. J. A., & Kraneveld, A. D. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00037 · Cited by 395
Toll-like receptors in the pathogenesis of neuroinflammation
Kumar, V. (2019) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2019.03.012 · Cited by 331
Metadata
- Authors
- Drouin-Ouellet, J., St-Amour, I., Saint-Pierre, M., Lamontagne-Proulx, J., Kriz, J., Barker, R. A., & Cicchetti, F.
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- Cicchetti, F.
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-12-07
- Volume
- 18
- Issue
- 6
- Pages
- pyu103-pyu103
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC4438545
- OpenAlex
- W2114037757
- Cited by
- 153
- References
- 63
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 19 · 2023: 11 · 2022: 21 · 2021: 19 · 2020: 17 · 2019: 12 · 2018: 19 · 2017: 7 · 2016: 6 · 2015: 5
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Parkinson Society Canada
- National Institute for Health and Care Research
- Parkinson's UK
- University of Cambridge
- Imperial College London
- Canadian Institutes of Health Research
- Fonds de Recherche du Québec - Santé
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, TLR2, TLR4, alpha-synuclein, neuroinflammation, microglia, innate immunity, circulating monocytes, B cells, caudate-putamen, synucleinopathies, dexamethasone, motor recovery, bioluminescence imaging
- MeSH terms
- Aged, Aged, 80 and over, Animals, Antiparkinson Agents, B-Lymphocytes, Brain, Dexamethasone, Disease Models, Animal, Female, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Middle Aged, Monocytes, Parkinson Disease, Time Factors, Up-Regulation, Case-Control Studies, Microglia, Green Fluorescent Proteins, Toll-Like Receptors, Toll-Like Receptor 2, Toll-Like Receptor 4, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.